Disruption of the glucagon receptor increases glucagon expression beyond α-cell hyperplasia in zebrafish

The glucagon receptor (GCGR) is a potential target for diabetes therapy. Several emerging GCGR antagonism-based therapies are under preclinical and clinical development. However, GCGR antagonism, as well as genetically engineered GCGR deficiency in animal models, are accompanied by α-cell hyperplasi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Qi, Zheng, Jihong, Jia, Jianxin, Xu, Ying, Bai, Xuanxuan, Chen, Xinhua, Zhang, Xiao-Kun, Wong, F. Susan, Zhang, Chao, Li, Mingyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Biochemistry and Molecular Biology 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719020/
https://www.ncbi.nlm.nih.gov/pubmed/36334626
http://dx.doi.org/10.1016/j.jbc.2022.102665

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719020/
https://www.ncbi.nlm.nih.gov/pubmed/36334626
http://dx.doi.org/10.1016/j.jbc.2022.102665

Ejemplares similares